Charles River Shanghai facility achieves regulatory milestones
Charles River Laboratories, a US contract research organisation that specialises in accelerating drug development, has received accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), the Canadian Council on Animal Care (CCAC) and the Shanghai Laboratory Animal Commission (SLAC) for its new facility in Shanghai, China.
Charles River Laboratories, a US contract research organisation that specialises in accelerating drug development, has received accreditation from the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), the Canadian Council on Animal Care (CCAC) and the Shanghai Laboratory Animal Commission (SLAC) for its new facility in Shanghai, China.
"These three accreditations are a milestone in Charles River's strategy to create a Center of Excellence in China," said James Foster, chief executive Charles River. "As a leading international CRO with GLP capabilities in China, we are replicating the company's high standards of research, safety, humane care and laboratory best practices."
The AAALAC report highlighted the Shanghai facility's strong commitment to its animal care programme, the state-of-the-art facility and equipment, as well as the dedicated and highly trained staff.
The CCAC also highlighted the facility's training, as well as its veterinary services, while the SLAC audit commended its animal welfare policies and emergency plan.